DESVENLAFAXINE SUCCINATE
| Brand name | PRISTIQ |
|---|---|
| Active ingredient | DESVENLAFAXINE SUCCINATE |
| Strength | EQ 25MG BASE |
| Dosage form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | August 2014 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 8269040 | July 2027 | substance |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.